Xenetic Biosciences
XBIO
4 hedge funds and large institutions have $1.44M invested in Xenetic Biosciences in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.16M |
| 2 |
Morgan Stanley
New York
|
+$21.1K |
| 3 |
Barclays
London,
United Kingdom
|
+$16K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$862 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1.39M | +$1.16M | +2,699 | New |
|
|
2
Morgan Stanley
New York
| $26K | +$21.1K | +49 | New |
|
|
3
Barclays
London,
United Kingdom
| $19K | +$16K | +37 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $1K | +$862 | +2 | New |
|
XBIO Hedge Fund Activity: Q4 2016 in Review
4 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2016, worth a combined $1.44M.
Buyers outnumbered sellers: 4 funds opened new XBIO positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $1.16M.
- 4 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $1.44M of Xenetic Biosciences stock for Q4 2016.
- 4 funds opened new Xenetic Biosciences positions in Q4 2016 and 0 closed out, a net change of +4 holders.
- The largest Xenetic Biosciences buyer in Q4 2016 was Royal Bank of Canada, an estimated $1.16M added.
Based on aggregated 13F filings for Q4 2016.